A DIAGNOSTIC MODEL FOR GERD PHENOTYPES BASED ON EPIDEMIOLOGICAL AND CLINICAL DATA OF THE RUSSIAN REGISTRY
Abstract
The aim of the study was to identify the epidemiological and clinical factors predisposing to non-erosive reflux disease (NERD), erosive esophagitis (EE) and Barrett’s esophagus in Russian population of patients, and to develop a diagnostic model for GERD phenotypes.
Materials and methods. 1433 patients with GERD from Moscow, Moscow region, St. Petersburg and Leningrad region were studied. During the study complaints and anamnestic data were gathered, anthropometry, tests for H. pylori infection and upper endoscopy were performed. Spearman rank correlation was used to identify the correlation of clinical characteristics with NERD, EE and Barrett’s esophagus. 880 patients with GERD (407 with NERD, 443 with EE, 27 with Barrett’s esophagus, 3 with esophageal stricture) were selected for correlation analysis due to the presence of all necessary parameters. To develop multivariable model for GERD phenotype diagnosis (EE/NERD), multivariate analyses was used. The prognostic value of multivariable model was determined based on ROC analysis.
Results. The prevalence of two main GERD phenotypes - EE and NERD - was approximately equal in the patients of Russian megapolises. Male gender was significantly negatively correlated with NERD development (p=0.002011). An inverse correlation was found between NERD and older age groups (p=0.002459), high waist circumference (WC) (p=0.003733), long duration of GERD symptoms (p=0.012984), the results of the GerdQ≥8 points (p=0.040030). In the group of patients with EE grade A-B, a significant inverse correlation was revealed with age over 40 years (p=0.002708), high body mass index (BMI) (p=0.020957), and high WC (p=0.001293). The male gender (p=0.000108) and the duration of GERD symptoms more than 3 years (p=0.028292) were significantly associated with severe grades of EE development. The male gender (p=0.007505) and not using of PPIs over the past 6 months (p=0.015930) were positively associated with Barrett's esophagus. Based on correlation analyses and predictive value 6 variables associated with EE/NERD were chosen: gender, age, GERDQ results, GERD symptoms duration, WC, BMI. Variables were divided into classes with similar risk with corresponding scores. The cut-off point (total score) with balance of sensitivity and specificity (Se≈Sp) was 549. Area under the curve (AUC) was 0,73, which indicates good quality of the diagnostic model.
Conclusion. Female gender, young age, normal BMI and WC, short duration of symptoms and GERD-Q less than 7 points were positively associated with NERD compared with EE among Russian patients. Male patients with long-term GERD symptoms, with overweight and obesity, who do not take PPIs are at high risk of Barrett's esophagus.
References
[2] Ribolsi M., Giordano A., Guarino M.P.L., Tullio A., Cicala M. New classifications of gastroesophageal reflux disease: an improvement for patient management? // Expert Review of Gastroenterology & Hepatology. – 2019. – 2019. – Vol. 13, № 8. – P. 761–769.
[3] Lazebnik LB, Masharova AA, Bordin DS, Vasil'ev IuV, Tkachenko EI, et al. Results of a multicenter trial "Epidemiology of Gastroesophageal Reflux Disease in Russia" (MEGRE) // Ter Arkh. – 2011. – 83(1). – P. 45-50.
[4] Nina Bandyopadhyay, Ronnie Fass, Takahisa Yamasaki, Colin Hemond. Pocket Handbook of Esophageal Disorders. Chapter 11. Gastroesophageal Reflux Disease (GERD). Springer Nature Switzerland AG 2019 85 N. DOI:10.1007/978-3-319-97331-9_11
[5] Bakulin I.G., Bordin D.S., Drapkina O.M., Zhuravleva M.S., Kokovina J.V., et al. Phenotypes od Gastroesophageal Reflux Disease in real clinical practice // Consilium Medicum. – 2019. – 21 (8). – P. 15-22.
[6] Vakil N., van Zanten S.V., Kahrilas P. et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidencebased consensus // Am J Gastroenterol. – 2006. – 101. P. 1900–1920.
[7] Miwa H, Kondo T, Oshima T, et al. Esophageal sensation and esophageal hypersensitivity - overview from bench to bedside // J Neurogastroenterol Motil. – 2010. – 16. – P. 353–362.
[8] Dickman R, Maradey-Romero C, Fass R. The role of pain modulators in esophageal disorders - no pain no gain // Neurogastroenterol Motil. – 2014. – 26. – P. 603–610.
[9] Hiltz S.W., Black E., Modlin I.M., Lane G., Johnson S.P., Schoenfeld P.S., Allen J.Brill J.V. AGA Medical Position Statement on the Management of Gastroesophageal Reflux Disease // Gastroenterology. – 2008. – 135: P. 1385–1391.
[10] Katz P.O., Gerson L.B., Vela M.F. ACG practice guidelines for the diagnosis and management of gastroesophageal reflux disease // Am. J. Gastroenterol. – 2013. – 108. – P. 308–328.
[11] Fock KM, Talley N., Goh K.L., Sugano K., Katerlaris P. et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett’s oesophagus // Gut. – 2016. – 65. – P. 1402–1415.
[12] Roman S, Gyawali CP, Savarino E et al. Ambulatory reflux monitoring for diagnosis of gastroesophageal reflux disease: update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil 2017; 29: 1–15.
[13] Zakharova N.V., Simanenkov V.I., Bakulin I., Sablin O.A., Ilchishina T.A., Zakharov D.V. Prevalence of Helicobacter pylori infection in gastroenterological patients in Saint-Petersburg // Pharmateca. – 2016. - №S5. – P. 33-39.
[14] Bakulinа N., Bakulin I., Ilchishina T. Epidemiological study on Helicobacter pylori infection among patients with dyspepsia in Saint-Petersburg (Russia) //Helicobacter. 2018;23(Suppl. 1):e12525. P.58. P04.02 DOI: 10.1111/hel.12525 [15] Bakulinа N., Simanenkov V.I., Bakulin I., Ilchishina T. Prevalence of H. pylori infection among physicians // Experimental and Clinical Gastroenterology. 2017;(12):20-24.
[16] Mari A., Mahroum N., Bragazzi N.L. et al. Demographics and Clinical and Endoscopic Characteristics of Patients with Helicobacter pylori Infection and Gastroesophageal Reflux Disease: A Case-Control Study // Gastroenterol Res Pract. – 2019: 3819893. doi: 10.1155/2019/3819893
[17] Mazzoleni F., Mazzoleni L.E., de Magalhães Francesconi C.F., Sander G.B., Von Reisswitz P.S. et al. Potential roles of Helicobacter pylori treatment, body mass index and waist circumference in the causation of erosive esophagitis: a randomized clinical trial (HEROES-GERD) // International Journal of Obesity. – 2019 Jun 13. https://doi.org/10.1038/s41366-019-0391-3.20
[18] Gastroesophageal reflux GWAS identifies risk loci that also associate with subsequent severe esophageal diseases // Jiyuan An // NATURE COMMUNICATIONS / https://doi.org/10.1038/s41467-019-11968-2/
[19] Psychological factors influence the gastroesophageal reflux disease (GERD) and their effect on quality of life among firefighters in South Korea // Jang SH, Ryu HS, Choi SC, Lee SY //Int J Occup Environ Health. 2016 Oct;22(4):315-320.
Epub 2016 Oct 3.
[20] Epidemiological risk factors in a comparison of a Barrett Esophagus Registry (BarretNET) and a case control population in Germany // Melissa Schmidt, Donna P Ankerst, Yiyao Chen, Maria Wiethaler, Julia Slotta-Huspenina, Karl-Friedrich Becker, Julia Horstmann, Florian Kohlmayer, Andreas Lehmann, Birgit Linkohr, Konstantin Strauch, Roland M Schmid, Anne S. Quante and Michael Quante // Cancer Prev Res February 17 2020 DOI: 10.1158/1940-6207. CAPR-19-0474.
[21] Blackshaw L.A., Bordin D.S., Brock C., Brokjaer A., Drewes A.M., et al. Pharmacologic treatments for esophageal disorders // Ann NY Acad Sci. – 2014. – 1325(1). – P. 23-39.
[22] Boeckxstaens G.E., Smout A. Systemic review: role of acid, weakly acid and weakly alkaline reflux in gastro-oesophageal reflux disease // Alim Pharmacol Ther. – 2010. – 32 (3). – P. 334–343.
[23] Cicala M., Emerenziani S., Guarino M.P., Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease // World J Gastroenterol. – 2013. – 19(39). – P. 6529-6535.
[24] Furuta T., Sugimoto M., Kodaira C., Nishino M., Yamade M., et al. CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole // Eur J Clin Pharmacol. – 2009. – 65(7). – P. 693-8.
[25] Richter JE. How to manage refractory GERD // Nat Clin Pract Gastroenterol Hepatol. 2007. –4. – P. 658–664.
CC BY-ND
A work licensed in this way allows the following:
1. The freedom to use and perform the work: The licensee must be allowed to make any use, private or public, of the work.
2. The freedom to study the work and apply the information: The licensee must be allowed to examine the work and to use the knowledge gained from the work in any way. The license may not, for example, restrict "reverse engineering."
2. The freedom to redistribute copies: Copies may be sold, swapped or given away for free, in the same form as the original.
